Radius Health Inc.'s osteoporosis therapy Tymlos (abaloparatide) is enjoying a free run at the US market with the recent delay to its rival Evenity (romosozumab) in the novel anabolic therapy space, but there still seem to be some blocks on its path to the EU market.
Radius highlighted a positive opinion from the European Medicines Agency’s main scientific committee, the CHMP, for abaloparatide-SC in July as...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
